Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy?

Drugs of Today

Volumn 37, Issue SUPPL. G, 2001, Pages 3-15

  Oettel, M ^a   Graser T ^a   Hoffmann, H ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANTIANDROGEN; DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL VALERATE; GESTAGEN; LAFAMME; LUTEINIZING HORMONE; PROGESTERONE DERIVATIVE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

BACTERIUM TRANSFORMATION; BONE ATROPHY; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG STRUCTURE; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ENVIRONMENT; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSTEOPOROSIS; PHARMACODYNAMICS; POSTMENOPAUSE; REVIEW;

EID: 0034787014     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Hormonal replacement therapy and endometrial cancer risk: A meta-analysis
2. Progestogens and menopause: Epidemiological studies of risks of endometrial and breast cancer
3. HRT dosing regimens; continuous versus cyclic - Pros and cons
4. Effects of estrogen or estrogen/progestogen regimens on heart disease risk factors in postmenopausal women
5. Therapeutic applications of micronized progesterone
6. The postmenopausal estrogen/progestogen interventions study: Primary outcomes in adherent women
7. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration
8. Oral micronized progesterone
9. Progesterone-induced changes in sleep in male subjects
10. Menopausal estrogen and estrogen-progestogen replacement therapy and breast cancer risk
11. Androgenic progestogens amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity
12. A 19-norprogestogen without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view
13. Experimentelle endokrinpharmakologie von dienogest
14. The preclinical and clinical profile of dienogest. A short overview
15. The pharmacological profile of dienogest
16. Hybrid progestogens - The example of dienogest
17. What is past is prologue: Estrogen/progestogen replacement tomorrow
18. Comparative pharmacology of newer progestogens
19. Organ targeting with the oral progestogen dienogest
20. Dienogest
21. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid
22. Relative potentiality of some contragestational agents on trauma induced deciduoma formation in immature rats
23. Interaction of antiprogestogens with progesterone receptors in rat uterus
24. Die wirkung von dienogest auf die hypothalamisch-hypophysäre achse: Ergebnisse einer pilotstudie
25. Endokrinologische befunde und die reaktivität der hypophyse gegenüber GnRH unter gestagenmonotherapie der endometriose mit dienogest
26. Das verhalten von parametern des leberstoffwechsels unter mittellangzeitanwendung des gestagens dienogest zur behandlung der endometriose
27. Zum einfluß eines neuen gestagens dienogest - Und seiner kombination mit ethinylestradiol auf die aktivität von biotransformationsreaktionen
28. Treatment of postmenopausal osteoporosis with transdermal estrogen
29. Estrogen replacement therapy and fractures in older women
30. The short term effects of conjugated estrogen on bone turnover in older women
31. Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy
32. Assessment of gestagen effects on bone metabolism in the rat
33. Possible synergistic effects of progestogen combination therapy on bone in the ovariectomised rat
34. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats
35. Steroidrezeptoren bei gestagenbehandlung der endometriose
36. Studie zur entwicklung eines geeigneten modells der endometriosis externa bei kaninchen und ratten und die effekte von dienogest und danazol
37. The treatment of endometriosis with dienogest
38. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestogens
39. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial cells in vitro
40. Reappraisal of progestogens in endometriosis therapy
41. Glycodelins
42. The postmenopausal uterus: The effect of hormone replacement therapy on the serum levels of secretory endometrial protein PP14/beta-lactoglobulin homologue
43. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest® for continuous combined hormone replacement therapy in postmenopausal women
44. Placental protein 14 (PP14) does not predict endometrial status under hormone replacement therapy
45. Non-protein bound dienogest in serum and salivary dienogest in women taking the oral contraceptives Certostat® and Valette®
46. Risk of breast cancer with progestogens in combination with estrogen as hormone replacement therapy
47. Postmenopausal estrogens - Opposed, unopposed, or none of above
48. Effects of oral contraceptives on breast epithelial proliferation
49. Normal and stable transfected cancer cell lines: Tools for a screening of progestogenic, antiprogestogenic and antiglucocorticoid substances
50. Growth stimulating effect of dienogest, a synthetic steroid, on rodent, canine, and primate mammary glands
51. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis
52. Clinical relevance of testosterone and dihydrotestosterone metabolism in women
53. Inhibition of skin 5-reductase by oral contraceptive progestogens in vitro
54. Klinische erfassung antiandrogener effekte von dienogest
55. Effects of the dienogest-containing oral contraceptive Valette® on skin and hair. Results of a postmarketing surveillance study
56. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®
57. Langzeituntersuchungen zum einfluß chlormadinon-, levonorgestrel- und dienogest-haltiger kontrazeptiva auf die stimmfunktion der frau
58. Der einfluß einer ethinylestradiol-dienogest-kombination auf die serum-androgen-konzentrationen
59. Effect of progestogens on IGF-I serum level in estrogen-treated postmenopausal women
60. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostendione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer
61. Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women
62. Effect of short-term medroxyprogesterone acetate on left ventricular mass: Role of insulin-like growth factor-1
63. Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH)
64. Breast-cancer risk following long-term oestrogen- and oestrogen-progestogen-replacement therapy
65. Oral estrogen retains potency as an aversion agent in eggs: Implications to studies of community ecology and wildlife management
66. Genotoxicity analysis and hazardousness prioritization of a group of chemicals
67. Zur biotransformation von dienogest durch mikroorganismen
68. Nitrile hydratase from Rhodococcus erythropolis: Metabolization of steroidal compounds with a nitrile group